Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

NEXT STORY
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
PREV STORY
Digital Radiography Market to Reach US$ 2,978.3 Mn by 2026, FDA Clearance to Philips and Other Companies to Enable Growth, says Fortune Business Insights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors

author_avatar
NASDAQ Market News

Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients

author_avatar
NASDAQ Market News

Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants

author_avatar
NASDAQ Market News